Frequency of Hospitalized Infections Is Reduced in Rheumatoid Arthritis Patients Who Received Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs after 2010
Joint Authors
Kawakami, Atsushi
Kawashiri, Shin-ya
Iwamoto, Naoki
Ichinose, Kunihiro
Shimizu, Toshimasa
Umeda, Masataka
Fukui, Shoichi
Nishino, Ayako
Koga, Tomohiro
Tamai, Mami
Nakamura, Hideki
Sato, Shuntaro
Origuchi, Tomoki
Source
Journal of Immunology Research
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-08-14
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
Background.
Biological disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic (ts) DMARDs are important in rheumatoid arthritis (RA) treatment.
The risk of hospitalized infection associated with bDMARDs/tsDMARDs in RA patients is unclear.
Methods.
We retrospectively analyzed the cases of the 275 RA patients with 449 treatment episodes who were administered a bDMARD/tsDMARD at Nagasaki University Hospital in July 2003–January 2015.
We determined the incidence and risk factors of infection requiring hospitalization in the patients during a 3-year observation period.
Results.
Thirty-five (12.7%) of the patients experienced a hospitalized infection.
The hospitalized infection risk did not differ significantly among several bDMARDs/tsDMARDs.
A multivariate analysis revealed that the comorbidities of chronic lung disease (adjusted HR 5.342, 95% CI 2.409–12.42, p<0.0001) and the initiation of bDMARDs/tsDMARDs before 2010 (adjusted HR 4.266, 95% CI 1.827–10.60, p=0.0007) are significant independent risk factors for hospitalized infection.
Compared to the before-2010 group, the group of patients whose treatment initiated in 2010 or later showed higher patient ages at the initiation of bDMARD/tsDMARD treatment and a higher rate of the use of prophylaxis with an antituberculosis agent, whereas the disease activities and number of the patients who received >5 mg of prednisolone were lower in the after-2010 group.
Conclusions.
This is the first report that the frequency of hospitalized infection significantly decreased when the patients were treated with a bDMARD or tsDMARD after 2010.
Our results indicate that the updated announcement of diagnosis and treatment criteria might contribute to a reduced risk of hospitalized infection and a better understanding of the use of bDMARDs/tsDMARDs by rheumatologists.
American Psychological Association (APA)
Ichinose, Kunihiro& Shimizu, Toshimasa& Umeda, Masataka& Fukui, Shoichi& Nishino, Ayako& Koga, Tomohiro…[et al.]. 2018. Frequency of Hospitalized Infections Is Reduced in Rheumatoid Arthritis Patients Who Received Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs after 2010. Journal of Immunology Research،Vol. 2018, no. 2018, pp.1-8.
https://search.emarefa.net/detail/BIM-1192748
Modern Language Association (MLA)
Ichinose, Kunihiro…[et al.]. Frequency of Hospitalized Infections Is Reduced in Rheumatoid Arthritis Patients Who Received Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs after 2010. Journal of Immunology Research No. 2018 (2018), pp.1-8.
https://search.emarefa.net/detail/BIM-1192748
American Medical Association (AMA)
Ichinose, Kunihiro& Shimizu, Toshimasa& Umeda, Masataka& Fukui, Shoichi& Nishino, Ayako& Koga, Tomohiro…[et al.]. Frequency of Hospitalized Infections Is Reduced in Rheumatoid Arthritis Patients Who Received Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs after 2010. Journal of Immunology Research. 2018. Vol. 2018, no. 2018, pp.1-8.
https://search.emarefa.net/detail/BIM-1192748
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1192748